Skip to main content
. 2022 Sep 2;14(17):4315. doi: 10.3390/cancers14174315

Figure 5.

Figure 5

Distribution of FLT3 mutations at relapse or progression in RATIFY trial [34]. D/R: diagnosis/relapse or progression; R: relapse or progression.